Genetic variants in central metabolic genes influence some but not all relations of inflammatory markers in a collective with polycystic ovary syndrome

References

• Alemzadeh R, Kichler J, Calhoun M. (2010). Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. Eur J Endocrinol 162:1093–9.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al., Androgen Excess Society. (2006). Androgen Excess Society position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome:an Androgen Excess Society guideline. J Clin Endocrinol Metab 91:4237–45.
   PubMed Web of Science ®Google Scholar
• Azziz R, Dumesic DA, Goodarzi MO. (2010). Polycystic ovary syndrome: an ancient disorder? Fertil Steril 95:1544–8.
   PubMed Web of Science ®Google Scholar
• Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. (2006). Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17:4–12.
   PubMed Web of Science ®Google Scholar
• Bensinger SJ, Tontonoz P. (2008). Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454:470–77.
   PubMed Web of Science ®Google Scholar
• Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. (2001). Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11:77–84.
   PubMedGoogle Scholar
• Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, Li Z, You L, Zhao J, Liu J, et al. (2011). Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 43:55–9.
   PubMed Web of Science ®Google Scholar
• Curti ML, Jacob P, Borges MC, Rogero MM, Ferreira SR. (2011). Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approach. J Obes 2011:497401.
   PubMedGoogle Scholar
• Dahlman I, Nilsson M, Jiao H, Hoffstedt J, Lindgren CM, Humphreys K, Kere J, Gustafsson JA, Arner P, Dahlman-Wright K. (2006). Liver X receptor gene polymorphisms and adipose tissue expression levels in obesity. Pharmacogenet Genomics 16:881–9.
   PubMed Web of Science ®Google Scholar
• Deakin S, Leviev I, Brulhart-Meynet MC, James RW. (2003). Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position -107, implicating the Sp1 transcription factor. Biochem J 372:643–9.
   PubMed Web of Science ®Google Scholar
• Deligeoroglou E, Kouskouti C, Christopoulos P. (2009). The role of genes in the polycystic ovary syndrome: predisposition and mechanisms. Gynecol Endocrinol 25:603–609.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Luque-Ramírez M, González F. (2011). Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril 95:1048–58.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL. (2003). Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46:625–33.
   PubMed Web of Science ®Google Scholar
• Ewens KG, Jones MR, Ankener W, Stewart DR, Urbanek M, Dunaif A, Legro RS, Chua A, Azziz R, Spielman RS, et al. (2011). FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS One 6:e16390.
   PubMed Web of Science ®Google Scholar
• Ewens KG, Jones MR, Ankener W, Stewart DR, Urbanek M, Dunaif A, Legro RS, Chua A, Azziz R, Spielman RS, et al. (2011). Type 2 diabetes susceptibility single-nucleotide polymorphisms are not associated with polycystic ovary syndrome. Fertil Steril 95:2538–541.
   PubMed Web of Science ®Google Scholar
• Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. (2006). The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res 47:2492–502.
   PubMed Web of Science ®Google Scholar
• Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. (1999). Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 48:437–41.
   PubMed Web of Science ®Google Scholar
• Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. (2011). Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 7:219–31.
   PubMed Web of Science ®Google Scholar
• Goodarzi MO, Louwers YV, Taylor KD, Jones MR, Cui J, Kwon S, Chen YD, Guo X, Stolk L, Uitterlinden AG, et al. (2011). Replication of association of a novel insulin receptor gene polymorphism with polycystic ovary syndrome. Fertil Steril 95:1736–41.
   PubMed Web of Science ®Google Scholar
• Gregor MF, Hotamisligil GS. (2011). Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415–45.
   PubMed Web of Science ®Google Scholar
• Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck B, Herrmann BL, Knebel B, Müller-Wieland D, Mann K, et al. (2005). The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62:573–79.
   PubMed Web of Science ®Google Scholar
• Hoffman WH, Burek CL, Waller JL, Fisher LE, Khichi M, Mellick LB. (2003). Cytokine response to diabetic ketoacidosis and its treatment. Clin Immunol 108:175–81.
   PubMed Web of Science ®Google Scholar
• Hong C, Tontonoz P. (2008). Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 18:461–67.
   PubMed Web of Science ®Google Scholar
• Jiang CQ, Lam TH, Liu B, Lin JM, Yue XJ, Jin YL, Cheung BM, Thomas GN. (2010). Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD. Obesity 18:1969–74.
   PubMed Web of Science ®Google Scholar
• Kellar KL, Iannone MA. (2002). Multiplexed microsphere-based flow cytometric assays. Exp Hematol 30:1227–37.
   PubMed Web of Science ®Google Scholar
• Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. (2001). Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453–5.
   PubMed Web of Science ®Google Scholar
• Ketterer C, Müssig K, Machicao F, Stefan N, Fritsche A, Häring HU, Staiger H. (2011). Genetic variation within the NR1H2 gene encoding liver X receptor β associates with insulin secretion in subjects at increased risk for type 2 diabetes. J Mol Med 89:75–81.
   PubMed Web of Science ®Google Scholar
• Kidd P. (2003). Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8:223–46.
   PubMedGoogle Scholar
• Knebel B, Janssen OE, Hahn S, Jacob S, Gleich J, Kotzka J, Muller-Wieland D. (2008). Increased low grade inflammatory serum markers in patients with Polycystic ovary syndrome (PCOS) and their relationship to PPARγamma gene variants. Exp Clin Endocrinol Diabetes 116:481–6.
   PubMed Web of Science ®Google Scholar
• Knebel B, Janssen OE, Hahn S, Nitzgen U, Jacob S, Haas J, Mack S, Müller-Wieland D, Kotzka J. (2009). Combined analyses of paraoxonase-1 and IGF-2 polymorphism in polycystic ovary syndrome. Dtsch Med Wochenschr 134:1040–46.
   PubMed Web of Science ®Google Scholar
• Knebel B, Lehr S, Janssen OE, Hahn S, Nitzgen U, Jacob S, Haas J, Müller-Wieland D, Kotzka J. (2011). Shift in the relation of inflammatory markers in a collective with polycystic ovary syndrome (PCOS). Diabetologie und Stoffwechsel 6:48–54.
   Web of Science ®Google Scholar
• Knebel B, Janssen OE, Hahn S, Jacob S, Nitzgen U, Haas J, Müller-Wieland D, Kotzka J. (2012). Genetic variations in SREBP-1 and LXRα are not directly associated to PCOS but contribute to the physiological specifics of the syndrome. Mol Biol Rep 39:6835–6842.
   PubMed Web of Science ®Google Scholar
• Legry V, Bokor S, Beghin L, Galfo M, Gonzalez-Gross M, Molnar D, Moreno LA, Amouyel P, Dallongeville J, Meirhaeghe A; on behalf of the HELENA Study Group. (2011). Associations between common genetic polymorphisms in the liver X receptor alpha and its target genes with the serum HDL-cholesterol concentration in adolescents of the HELENA Study. Atherosclerosis 216:166–9.
   PubMed Web of Science ®Google Scholar
• Legry V, Cottel D, Ferrières J, Chinetti G, Deroide T, Staels B, Amouyel P, Meirhaeghe A. (2008). Association between liver X receptor alpha gene polymorphisms and risk of metabolic syndrome in French populations. Int J Obes (Lond) 32:421–8.
   PubMed Web of Science ®Google Scholar
• Leviev I, Negro F, James RW. (1997). Two alleles of the human paraoxonase gene produce different amounts of mRNA, An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 17:2935–9.
   PubMed Web of Science ®Google Scholar
• Lindholm A, Blomquist C, Bixo M, Dahlbom I, Hansson T, Sundström Poromaa I, Burén J. (2011). No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight–matched controls. Hum Reprod 26:1478–85.
   PubMed Web of Science ®Google Scholar
• Luque-Ramírez M, Escobar-Morreale HF. (2010). Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin–6 concentrations. Horm Metab Res 42:815–20.
   PubMed Web of Science ®Google Scholar
• Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. (1998). Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification.FEBS Lett 423:57–60.
   PubMed Web of Science ®Google Scholar
• Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlösser HW, Brabant G, Schöfl C. (2004). The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 150:525–32.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Maitra A. (2010). Molecular and genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res 131:743–60.
   PubMed Web of Science ®Google Scholar
• Price ET, Pacanowski MA, Martin MA, Cooper-Dehoff RM, Pepine CJ, Zineh I, Johnson JA. (2011). Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. Pharmacogenet Genomics 21:333–40.
   PubMed Web of Science ®Google Scholar
• Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. (2005). Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 90:6014–21.
   PubMed Web of Science ®Google Scholar
• Ramos Cirilo PD, Rosa FE, Moreira Ferraz MF, Rainho CA, Pontes A, Regina Rogatto S. (2012). Genetic polymorphisms associated with steroids metabolism and insulin action in polycystic ovary syndrome. Gynecol Endocrinol 28:194–4.
   Google Scholar
• Rodríguez S, Gaunt TR, O’Dell SD, Chen XH, Gu D, Hawe E, Miller GJ, Humphries SE, Day IN. (2004). Haplotypic analyses of the IGF2-INS-TH gene cluster in relation to cardiovascular risk traits. Hum Mol Genet 13:715–25.
   Google Scholar
• Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–7. Epub 2011 Aug 9.
   Google Scholar
• Samy N, Hashim M, Sayed M, Said M. (2009). Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers 26:163–70.
   PubMed Web of Science ®Google Scholar
• San Millán JL, Alvarez-Blasco F, Luque-Ramírez M, Botella-Carretero JI, Escobar-Morreale HF. (2006). The PON1-108C/T polymorphism, and not the polycystic ovary syndrome, is an important determinant of reduced serum paraoxonase activity in premenopausal women. Hum Reprod 21:3157–61.
   PubMed Web of Science ®Google Scholar
• San Millán JL, Cortón M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. (2004). Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 89:2640–46.
   PubMed Web of Science ®Google Scholar
• San-Millán JL, Escobar-Morreale HF. (2010). The role of genetic variation in peroxisome proliferator–activated receptors in the polycystic ovary syndrome (PCOS): an original case-control study followed by systematic review and meta-analysis of existing evidence. Clin Endocrinol (Oxf) 72:383–92.
   PubMed Web of Science ®Google Scholar
• Song Y, Simonyi K, Thomas R, Zhang A, Huang I, Aguilera A. (2000). Simultaneous quantitation of 5 phosphorylated proteins using the Bio-Plex Protein Array System. Bio-Rad Bull 2632.
   Google Scholar
• Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, Pavlaki A, Stergianos S, Poulasouchidou M, Tzellos TG, et al. (2011). Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 17:741–60.
   PubMed Web of Science ®Google Scholar
• Unluturk, U., Harmanci, A., Kocaefe, C. Yildiz BO. (2007). The genetic basis of the polycystic ovary syndrome:a literature review including discussion of PPAR-gamma. PPAR Research, 49109.
   PubMed Web of Science ®Google Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA. (2010). Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 95:2038–49.
   PubMed Web of Science ®Google Scholar
• Wild RA, Rizzo M, Clifton S, Carmina E. (2011). Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 95:1073–9.
   PubMed Web of Science ®Google Scholar
• Zawadski JK, Dunai FA. (1992). Diagnostic criteria for polycystic ovary syndrome:toward a rational approach. In: Dunaif A, Givens JR, Hasettine FP, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications, pp. 377–84.
   Google Scholar
• Zhao C, Dahlman-Wright K. (2010). Liver X receptor in cholesterol metabolism. J Endocrin 204:233–240.
   PubMed Web of Science ®Google Scholar